China is the bigger Asthma & COPD Drugs market: $4 Bn against $900 Mn in 2023, about 4.4 times as large.
India grows faster: 7% a year, against 5.5%. The gap still grows from $3.1 Bn to $5 Bn by 2033.
Clinical research: 175 active trials in China, 16 in India.
| Measure |  China |  India |
|---|---|---|
| Market size, 2023 | $4 Bn | $900 Mn |
| Market size, 2033 projected | $6.8 Bn | $1.8 Bn |
| Growth a year (CAGR) | 5.5% | 7% |
| Money added, 2023–2033 | $2.8 Bn | $871 Mn |
| Share of the world market | 8% | 1.8% |
| Size rank of 24 countries | #2 | #12 |
| Market per person, 2023 | $2.83 | $0.61 |
| Active clinical trials | 175 | 16 |
| Full report | China report | India report |
Year by year, 2023 to 2033
China India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Asthma & COPD Drugs, China or India?
China is the bigger Asthma & COPD Drugs market: $4 Bn against $900 Mn in 2023, about 4.4 times as large.
Which grows faster in Asthma & COPD Drugs, China or India?
India grows faster: 7% a year, against 5.5%. The gap still grows from $3.1 Bn to $5 Bn by 2033.
More Asthma & COPD Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.